Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydros/Hydros-TA for knee osteoarthritis pain
NL-OMON40374Active, not recruiting
- Sponsor
- Carbylan Therapeutics
- Start
- Oct 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of hyaluronic acid + triamcinolone acetonide, hydrocodone and triamcinolone acetonide in osteoarthritis (OA) and knee osteoarthritis (OA) (3 arms), sponsored by Carbylan Therapeutics. Primary endpoints: Reduction of osteoarthritis symptoms at 2 weeks and Reduction of osteoarthritis symptoms at 26 weeks. Started Oct 2013; status: active, not recruiting.
02
Drugs
hyaluronic acid + triamcinolone acetonidehydrocodonetriamcinolone acetonide
03
Conditions
osteoarthritis (OA)knee osteoarthritis (OA)
Beyond the preview
Go deeper on NL-OMON40374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40374.